The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $76.16

Today's change-1.93 -2.47%
Updated September 28 1:32 PM EDT. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $76.16

Today's change-1.93 -2.47%
Updated September 28 1:32 PM EDT. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc down (U.S.)$1.93

Alnylam Pharmaceuticals Inc is sharply lower today, dropping (U.S.)$1.93 or 2.47% to (U.S.)$76.16. Over the last five days, shares have lost 2.10% and are down 19.10% for the last year to date. This security has underperformed the S&P 500 by 19.38% during the last year.

Key company metrics

  • Open(U.S.) $78.22
  • Previous close(U.S.) $78.09
  • High(U.S.) $78.87
  • Low(U.S.) $75.59
  • Bid / Ask(U.S.) $76.07 / (U.S.) $76.23
  • YTD % change-19.10%
  • Volume228,730
  • Average volume (10-day)525,151
  • Average volume (1-month)477,479
  • Average volume (3-month)787,763
  • 52-week range(U.S.) $49.96 to (U.S.) $110.75
  • Beta2.47
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.24
Updated September 28 1:32 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,204.91%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.64%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue9786
Total other revenue--------
Total revenue9786
Gross profit--------
Total cost of revenue--------
Total operating expense10111710085
Selling / general / administrative18211716
Research & development83968369
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-92-110-93-78
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-90-103-91-77
Income after tax-90-103-91-77
Income tax, total0000
Net income-90-103-91-77
Total adjustments to net income--------
Net income before extra. items-90-103-91-77
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-90-103-91-77
Inc. avail. to common incl. extra. items-90-103-91-77
Diluted net income-90-103-91-77
Dilution adjustment--------
Diluted weighted average shares86858585
Diluted EPS excluding extraordinary itemsvalue per share-1.05-1.21-1.07-0.91
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.05-1.21-1.07-0.91